[Antibiotics and kidney]

No abstract is available for this paper.

• Publication year

  2000

• Venue

  ˜Le œInfezioni in medicina

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 12709599
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prediction of Creatinine Clearance from Serum Creatinine in Patients with Rheumatoid Arthritis: Comparison of Six Formulae and One Nomogram

  2000cited by this paper
• Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis.

  1999cited by this paper
• Pharmacokinetics of once-daily gentamicin dosing in pediatric patients.

  1998cited by this paper
• The comparative efficacy and safety of teicoplanin and vancomycin.

  1996cited by this paper
• Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties.

  1995cited by this paper
• Nephrotoxicity of amphotericin B.

  1994cited by this paper
• Clinical use of liposomal and lipid-complexed amphotericin B.

  1994cited by this paper
• Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS

  1993cited by this paper
• Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring.

  1993cited by this paper
• Mechanism of ischemia-enhanced aminoglycoside binding and uptake by proximal tubule cells.

  1993cited by this paper
• Liposomal and Lipid Formulations of Amphotericin B

  1992cited by this paper
• Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis.

  1992cited by this paper
• Simplified dosing and monitoring of vancomycin for the burn care clinician.

  1992cited by this paper
• Effect of salt supplementation on amphotericin B nephrotoxicity.

  1991cited by this paper
• Renal aspects of therapy for human immunodeficiency virus and associated opportunistic infections.

  1991cited by this paper
• Nephrotoxicity of vancomycin, alone and with an aminoglycoside.

  1990cited by this paper
• Risk factors for Amphotericin B-associated nephrotoxicity.

  1989cited by this paper
• [Acute interstitial nephritis due to drugs].

  1988cited by this paper
• Aminoglycoside nephrotoxicity.

  1988cited by this paper
• Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation.

  1988cited by this paper
• Allergic interstitial nephritis: clinical features and pathogenesis.

  1988influential reference
• Principles and practice of infectious diseases

  1987cited by this paper
• Vancomycin enhancement of experimental tobramycin nephrotoxicity

  1986cited by this paper
• Prevention of Ischemic/Toxic Acute Renal Failure in Humans

  1984cited by this paper
• Aminoglycoside Nephrotoxicity in Humans

  1983cited by this paper
• Clinical and pathophysiologic aspects of aminoglycoside nephrotoxicity.

  1982cited by this paper
• Vancomycin therapy in patients with impaired renal function: a nomogram for dosage.

  1981cited by this paper
• Nomograms for Drug Use in Renal Disease

  1981cited by this paper
• Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin.

  1980cited by this paper
• Drug therapy in renal failure: dosing guidelines for adults. Part I: Antimicrobial agents, analgesics.

  1980cited by this paper
• Effect of co-trimoxazole on normal creatinine clearance.

  1978cited by this paper
• Renal failure associated with demeclocycline in cirrhosis.

  1977cited by this paper
• Deterioration in renal function in association with co-trimoxazole therapy.

  1973cited by this paper
• Vancomycin for Staphylococcal Shunt Site Infections in Patients on Regular Haemodialysis

  1970cited by this paper

• No citing papers are available for this paper.